C-Met Mutated Non-Small Cell Lung Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Novartis, Apollomics Inc., Abbvie, Janssen Research and Development

C-Met Mutated Non-Small Cell Lung Cancer Pipeline constitutes 5+ key companies continuously working towards developing 5+ C-Met Mutated Non-Small Cell Lung Cancer treatment therapies, analyzes DelveInsight.

C-Met Mutated Non-Small Cell Lung Cancer Overview:

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by an overexpression of the C-Met tyrosine kinase receptor, which is typically found in epithelial cells. Activation of C-Met leads to the phosphorylation of specific tyrosine residues (Y1003, Y1313, Y1230/1234/1235, Y1349, and Y1365), triggering multiple downstream signaling pathways such as RAS/ERK, PI3K/AKT, and cSRC kinase pathways. Due to SRC activation, C-Met is recognized as a key driver of epithelial-mesenchymal transition, promoting high levels of hepatocyte growth factor (HGF) and intratumoral C-Met expression-factors that are closely linked to NSCLC biology and prognosis. NSCLC is classified into three main types based on cellular morphology: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Major risk factors for NSCLC include smoking, radiation exposure, and contact with hazardous substances such as asbestos, arsenic, and chromium.

Request for a detailed insights report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/report-store/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the C-Met Mutated Non-Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report

DelveInsight's C-Met Mutated Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for C-Met Mutated Non-Small Cell Lung Cancer treatment.
Key C-Met Mutated Non-Small Cell Lung Cancer companies such as Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others are evaluating new drugs for C-Met Mutated Non-Small Cell Lung Cancer to improve the treatment landscape.
Promising C-Met Mutated Non-Small Cell Lung Cancer pipeline therapies in various stages of development include EGF-816 (Nazartinib), APL 101 (Bozitinib), and others.

Recent breakthroughs in the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Segment:

In May 2020, Novartis received FDA approval for Tabrecta, an oral MET inhibitor specifically targeting metastatic NSCLC with mutations leading to MET exon 14 skipping (METex14). This approval marked the first therapy designed for this particular genetic mutation. Clinical trials demonstrated an overall response rate of 68% in treatment-naïve patients and 41% in previously treated patients.

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the C-Met Mutated Non-Small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for C-Met Mutated Non-Small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the C-Met Mutated Non-Small Cell Lung Cancer market.

Download our free sample page report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

C-Met Mutated Non-Small Cell Lung Cancer Emerging Drugs

EGF-816 (Nazartinib): Novartis Oncology
APL 101 (Bozitinib): Appolomics Inc.

C-Met Mutated Non-Small Cell Lung Cancer Companies

There are over five key companies actively developing therapies for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC). Among them, companies such as Novartis Oncology and others have drug candidates currently in mid-to-advanced stages of development, including Phase III clinical trials.

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

C-Met Mutated Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

C-Met Mutated Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging C-Met Mutated Non-Small Cell Lung Cancer Therapies and Key Companies: C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Product Type
• C-Met Mutated Non-Small Cell Lung Cancer By Stage
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Route of Administration
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Molecule Type

Download C-Met Mutated Non-Small Cell Lung Cancer Sample report to know in detail about the C-Met Mutated Non-Small Cell Lung Cancer treatment market @ C-Met Mutated Non-Small Cell Lung Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. C-Met Mutated Non-Small Cell Lung Cancer Current Treatment Patterns
4. C-Met Mutated Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. C-Met Mutated Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. C-Met Mutated Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. C-Met Mutated Non-Small Cell Lung Cancer Discontinued Products
13. C-Met Mutated Non-Small Cell Lung Cancer Product Profiles
14. C-Met Mutated Non-Small Cell Lung Cancer Key Companies
15. C-Met Mutated Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. C-Met Mutated Non-Small Cell Lung Cancer Unmet Needs
18. C-Met Mutated Non-Small Cell Lung Cancer Future Perspectives
19. C-Met Mutated Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.